tetanus toxoid

Summary

Top Publications

  1. pmc Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis
    Suba Nookala
    Center for Biotechnology, Anna University, Chennai 600025, India
    Infect Immun 72:2598-604. 2004
  2. ncbi Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age
    Roger Baxter
    Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 30:e41-8. 2011
  3. pmc Transcriptomic response of porcine PBMCs to vaccination with tetanus toxoid as a model antigen
    Marcel Adler
    Leibniz Institute for Farm Animal Biology FBN, Institute for Genome Biology, Dummerstorf, Germany
    PLoS ONE 8:e58306. 2013
  4. pmc Tetanus toxoid immunization to reduce mortality from neonatal tetanus
    Hannah Blencowe
    London School of Hygiene and Tropical Medicine, London, UK
    Int J Epidemiol 39:i102-9. 2010
  5. ncbi Gene expression after vaccination of mice with formulations of diphtheria toxoid or tetanus toxoid and different adjuvants: identification of shared and vaccine-specific genes in spleen lymphocytes
    Karin Regnstrom
    Department of Pharmacy, Uppsala University, PO Box 580, SE 751 23 Uppsala, Sweden
    Vaccine 21:2307-17. 2003
  6. ncbi Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients
    Adriaan Bins
    Divisions of Immunology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
    J Immunother 30:234-9. 2007
  7. pmc Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum
    C Grangette
    Département de Microbiologie des Ecosystèmes, Institut Pasteur de Lille, 59019 Lille Cedex, France
    Infect Immun 69:1547-53. 2001
  8. ncbi Persistence of mucosal and systemic immune responses following sublingual immunization
    Donatella R M Negri
    Department of Infectious, Parasitic and Immune Mediated Diseases, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Vaccine 28:4175-80. 2010
  9. pmc Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
    A Boutonnier
    , , Institut Pasteur, 75724 Paris Cedex 15, France
    Infect Immun 69:3488-93. 2001
  10. pmc Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice
    Viviana Buffa
    Clinical Sciences, St George s University of London, London, United Kingdom
    PLoS ONE 7:e50529. 2012

Detail Information

Publications265 found, 100 shown here

  1. pmc Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis
    Suba Nookala
    Center for Biotechnology, Anna University, Chennai 600025, India
    Infect Immun 72:2598-604. 2004
    ..in lymphatic filariasis, the effect of concurrent Wuchereria bancrofti infection on the immune response to tetanus toxoid (TT) following tetanus vaccination was studied in 20 asymptomatic microfilaremic (MF) patients, 20 patients ..
  2. ncbi Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age
    Roger Baxter
    Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 30:e41-8. 2011
    An investigational quadrivalent Neisseria meningitidis serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) has been developed to expand available options for vaccination against invasive meningococcal disease.
  3. pmc Transcriptomic response of porcine PBMCs to vaccination with tetanus toxoid as a model antigen
    Marcel Adler
    Leibniz Institute for Farm Animal Biology FBN, Institute for Genome Biology, Dummerstorf, Germany
    PLoS ONE 8:e58306. 2013
    ..Vaccination with tetanus toxoid was used as a model for a mixed Th1 and Th2 immune response in pig...
  4. pmc Tetanus toxoid immunization to reduce mortality from neonatal tetanus
    Hannah Blencowe
    London School of Hygiene and Tropical Medicine, London, UK
    Int J Epidemiol 39:i102-9. 2010
    ..Large reductions in neonatal tetanus deaths have been reported following major increases in the coverage of tetanus toxoid immunization, yet the level of evidence for the mortality effect of tetanus toxoid immunization is ..
  5. ncbi Gene expression after vaccination of mice with formulations of diphtheria toxoid or tetanus toxoid and different adjuvants: identification of shared and vaccine-specific genes in spleen lymphocytes
    Karin Regnstrom
    Department of Pharmacy, Uppsala University, PO Box 580, SE 751 23 Uppsala, Sweden
    Vaccine 21:2307-17. 2003
    We immunized mice with four different combinations of diphtheria toxoid or tetanus toxoid with aluminum phosphate or Freund's adjuvant and studied the resulting gene expression profiles in spleen lymphocytes...
  6. ncbi Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients
    Adriaan Bins
    Divisions of Immunology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
    J Immunother 30:234-9. 2007
    ..E27L (ELAGIGILTV), tyrosinase(368-376) N375Q (YMDGTMSQV), and gp100(209-217) T210M (IMQVPFSV), admixed with tetanus toxoid and granulocyte-monocyte colony stimulating factor...
  7. pmc Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum
    C Grangette
    Département de Microbiologie des Ecosystèmes, Institut Pasteur de Lille, 59019 Lille Cedex, France
    Infect Immun 69:1547-53. 2001
    ..These results demonstrate that recombinant lactobacilli can induce specific humoral (protective) and mucosal antibodies and cellular immune response against protective antigens upon nasal administration...
  8. ncbi Persistence of mucosal and systemic immune responses following sublingual immunization
    Donatella R M Negri
    Department of Infectious, Parasitic and Immune Mediated Diseases, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    Vaccine 28:4175-80. 2010
    ..purpose, we evaluated the efficacy and durability of immune response induced by sublingual immunization with tetanus toxoid (TT) as an antigen in the presence of mucosal adjuvants, such as E...
  9. pmc Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
    A Boutonnier
    , , Institut Pasteur, 75724 Paris Cedex 15, France
    Infect Immun 69:3488-93. 2001
    ..cholerae O139 (pmLPS) was prepared by derivatization of the pmLPS with adipic acid dihydrazide and coupling to tetanus toxoid (TT) by carbodiimide-mediated condensation...
  10. pmc Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice
    Viviana Buffa
    Clinical Sciences, St George s University of London, London, United Kingdom
    PLoS ONE 7:e50529. 2012
    ..We assess their ability to enhance antibody responses to HIV-1 CN54gp140 (gp140) and Tetanus toxoid (TT) in systemic and vaginal compartments. A number of trends were observed by route of administration...
  11. ncbi Serological characterisation of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid
    C Lugowski
    Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland
    FEMS Immunol Med Microbiol 16:21-30. 1996
    The covalent conjugates of oligosaccharide core: Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid have been prepared using reaction of reductive amination...
  12. ncbi Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine
    Michael E Pichichero
    University of Rochester Medical Center, Rochester, New York 14642, USA
    J Pediatr 151:43-9, 49.e1-2. 2007
    ....
  13. ncbi Maternal and neonatal tetanus
    Martha H Roper
    Weybridge, VT, USA
    Lancet 370:1947-59. 2007
    ..Although easily prevented by maternal immunisation with tetanus toxoid vaccine, and aseptic obstetric and postnatal umbilical-cord care practices, maternal and neonatal tetanus ..
  14. pmc Tetanus in England and Wales, 1984-2000
    A A Rushdy
    Immunisation Division, Public Health Laboratory Service Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW1 5EQ
    Epidemiol Infect 130:71-7. 2003
    ..High childhood tetanus vaccination coverage remains a priority. As the disease becomes rarer, enhanced tetanus case surveillance is essential for tetanus immunization policy evaluation...
  15. pmc Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam
    E Y Konadu
    National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892 2720, USA
    Infect Immun 68:1529-34. 2000
    ..O-SP) was activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) and bound to tetanus toxoid (TT) with adipic acid dihydrazide as a linker (SPA-TT(1)) or directly (SPA-TT(2))...
  16. ncbi Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants
    Colin D Marchant
    Boston University Medical Center, Boston, MA 02118, USA
    Pediatr Infect Dis J 29:48-52. 2010
    Study assessed the immunogenicity and safety of an investigational Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) in infants.
  17. ncbi Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine
    Terry Nolan
    Vaccine and Immunisation Research Group, Murdoch Children s Research Institute and School of Population Health, University of Melbourne, Victoria, Australia
    Pediatr Infect Dis J 30:190-6. 2011
    Neisseria meningitidis serogroups B, C, and Y cause most meningococcal disease in industrialized countries. A Haemophilus influenzae type b-meningococcal serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) was evaluated.
  18. ncbi Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of
    Juan C Tejedor
    Mostoles Hospital, Madrid, Spain
    Pediatr Infect Dis J 27:579-88. 2008
    A combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) may be a convenient alternative to separate Hib and MenC conjugate vaccines.
  19. pmc Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom
    Ray Borrow
    PHLS Meningococcal Reference Unit, Withington Hospital, Manchester, United Kingdom
    Infect Immun 71:5549-55. 2003
    ..Thus, in infants a one- or two-dose schedule of this MCC vaccine, conjugated to tetanus toxoid (TT), may suffice...
  20. ncbi Adjuvant effect of aqueous extract of Rhodiola imbricata rhizome on the immune responses to tetanus toxoid and ovalbumin in rats
    K P Mishra
    Immunomodulation Laboratory, Defense Institute of Physiology and Allied Sciences, Delhi, India
    Immunopharmacol Immunotoxicol 32:141-6. 2010
    ..The efficacy of RAE was determined by using strong antigen tetanus toxoid (TT) and weak antigen Ovalbumin (OVA)...
  21. ncbi Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers
    P Richmond
    Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, London, United Kingdom
    J Infect Dis 183:160-3. 2001
    ..The protein conjugate was diphtheria mutant toxoid in 2 vaccines (MCC-CRM(197)) and was tetanus toxoid in the third (MCC-TT)...
  22. ncbi A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
    M Knuf
    Zentrum für Kinder und Jugendmedizin, Johannes Gutenberg University, Germany
    Vaccine 28:744-53. 2010
    ..The safety profile was comparable to licensed controls. The new ACWY-TT conjugate vaccine promises high seroprotection levels against meningococcal disease from 1 year of age...
  23. ncbi Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial
    Timo Vesikari
    Vaccine Research Center, University of Tampere Medical School, Tampere, Finland
    Vaccine 29:4274-84. 2011
    Co-administration of meningococcal ACWY-tetanus toxoid conjugate vaccine (ACWY-TT) with MMRV vaccine was investigated in 1000 12-23-month old children randomized (3:3:1:1) to receive co-administered ACWY-TT+MMRV, or a single dose of ACWY-..
  24. ncbi Porcine genome-wide gene expression in response to tetanus toxoid vaccine
    S Ponsuksili
    Research Institute for the Biology of Farm Animals FBN Dummerstorf, Research Group Functional Genomics
    Dev Biol (Basel) 132:185-95. 2008
    The very early in vivo response to immune stimuli was studied using tetanus toxoid as a model antigen known to induce Th1 and Th2 responses. Eighteen weaning piglets were vaccinated subcutaneously with tetanus toxoid...
  25. ncbi Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid
    Gianfranco Di Genova
    Cancer Sciences Division, University of Southampton School of Medicine, Southampton, UK
    Eur J Immunol 40:976-85. 2010
    ..We previously observed this bystander effect in healthy human subjects following recall vaccination with tetanus toxoid (TT)...
  26. ncbi Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile
    Ziad A Memish
    National Guard Affairs, King Abdulaziz Medical City, Riyadh, Saudi Arabia
    Pediatr Infect Dis J 30:e56-62. 2011
    ..Immunogenicity and safety of the investigational ACWY vaccine conjugated with tetanus toxoid (ACWY-TT, GlaxoSmithKline Biologicals) were evaluated in 1501 healthy 2- to 10-year-old children in the ..
  27. ncbi Seroprotection against tetanus in patients attending an emergency department in Belgium and evaluation of a bedside immunotest
    Muriel Stubbe
    Department of Emergency Medicine, Erasme University Hospital, Brussels, Belgium
    Eur J Emerg Med 14:14-24. 2007
    ..In most emergency departments, tetanus prophylaxis currently relies on vaccination history. Bedside evaluation of tetanus immunity may improve this process...
  28. ncbi Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age
    Gary S Marshall
    Department of Pediatrics, University of Louisville School of Medicine, Louisville, KY 40202, USA
    Pediatr Infect Dis J 29:469-71. 2010
    ..A total of 236 infants received a fourth Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) dose at 12 to 15 months...
  29. ncbi Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults
    P Richmond
    Immunobiology Unit, Institute of Child Health, 30 Guilford Street, London, UK
    Vaccine 18:641-6. 1999
    ..safety and immunogenicity of a single dose of a new serogroup C O-deacetylated meningococcal polysaccharide-tetanus toxoid conjugate vaccine in 30 healthy adult volunteers...
  30. ncbi A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants
    Terry Nolan
    Murdoch Children s Research Institute and School of Population Health, The University of Melbourne, Australia
    Vaccine 25:8487-99. 2007
    ..Hib-MenCY-TT administered according to the current US Hib vaccine schedule has the potential to induce protective antibodies against Hib and meningococcal-CY disease in infants and toddlers...
  31. ncbi Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers
    D Mahalingam
    Malaysian Palm Oil Board, Selangor, Malaysia
    Eur J Clin Nutr 65:63-9. 2011
    ..The objective of this study was to assess the effects of tocotrienol-rich fraction (TRF) supplementation on immune response following tetanus toxoid (TT) vaccine challenge in healthy female volunteers.
  32. pmc Reduction of human anti-tetanus toxoid antibody in hu-PBL-SCID mice by immunodominant peptides of tetanus toxoid
    D J Jackson
    International Blood Group Reference Laboratory, Bristol Institute of Transfusion Sciences, University of Bristol, Bristol, UK
    Clin Exp Immunol 137:245-52. 2004
    ..a preclinical system was developed to test the effect of immunodominant peptides from a common antigen, tetanus toxoid (TT), on the long-term human anti-TT response...
  33. ncbi Impaired cellular immune response to tetanus toxoid but not to cytomegalovirus in effectively HAART-treated HIV-infected children
    Laia Alsina
    Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu Universitat de Barcelona, Barcelona, Spain
    Vaccine 31:2417-9. 2013
    ..We compared the cellular immune response (assessed in terms of IFN-γ production) to tetanus toxoid and to cytomegalovirus in a series of 13 HIV-perinatally-infected children and adolescents with optimal ..
  34. ncbi Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group
    C Confavreux
    European Database for Multiple Sclerosis Coordinating Center and the Service de Neurologie A, H pital Neurologique, Lyons, France
    N Engl J Med 344:319-26. 2001
    ..22 to 1.08). Analyses based on risk periods of one and three months yielded similar results. CONCLUSIONS: Vaccination does not appear to increase the short-term risk of relapse in multiple sclerosis...
  35. ncbi Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid
    Tine Rugh Poulsen
    Department for Antibody Discovery, Symphogen A S, Lyngby, Denmark
    J Immunol 179:3841-50. 2007
    ..The observed genetic diversity among tetanus toxoid-specific plasma cells indicate that human polyclonal repertoires are limited to the order of 100 B cell clones ..
  36. pmc Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults
    Uwe Schauer
    Klinik für Kinder und Jugendmedizin der Ruhr Universität, Bochum, Germany
    Clin Diagn Lab Immunol 10:202-7. 2003
    ..for capsular polysaccharides of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) and for tetanus toxoid were measured in serum samples of 386 age-stratified subjects...
  37. ncbi Tetanus surveillance--United States, 1998--2000
    F Brian Pascual
    Epidemiology and Surveillance Division, National Immunization Program, USA
    MMWR Surveill Summ 52:1-8. 2003
    Tetanus is a severe and often fatal infection. The incidence of reported cases in the United States has declined steadily since introduction of tetanus toxoid vaccines in the 1940s.
  38. ncbi Serological characterization of anti-endotoxin serum directed against the conjugate of oligosaccharide core of Escherichia coli type R4 with tetanus toxoid
    Jolanta Lukasiewicz
    Department of Immunochemistry, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53 114 Wroclaw, Poland
    FEMS Immunol Med Microbiol 37:59-67. 2003
    The covalent conjugate of oligosaccharide core of Escherichia coli type R4 with tetanus toxoid was prepared using reaction of reductive amination...
  39. ncbi Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization
    Cristina Cellerai
    Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    Eur J Immunol 37:1129-38. 2007
    ..thus investigated the kinetics and changes of IL-7Ralpha and anti-apoptotic protein Bcl-2 expression levels in tetanus toxoid (TT)-specific CD4(+ )T cells at different time points prior and after TT re-immunization of TT-immune ..
  40. ncbi Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay
    Stephanie Mayer
    Department of Hematology and Oncology, University Hospital of Regensburg, Germany
    Immunobiology 205:282-9. 2002
    b>Tetanus toxoid (TT) is an antigen known to induce strong T cell specific immune responses in humans after vaccination...
  41. ncbi Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous V(H) genes
    John de Kruif
    Merus Biopharmaceuticals, Utrecht, The Netherlands
    J Mol Biol 387:548-58. 2009
    ..a large collection of antibody heavy (H) chains harvested from the blood of two human donors immunized with tetanus toxoid (TT) vaccine...
  42. ncbi Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres
    Manish Diwan
    Faculty of Pharmacy and Pharmaceutical Sciences, 3118 Dentistry Pharmacy Center, University of Alberta, Edmonton, T6G 2N8 Canada
    J Control Release 85:247-62. 2002
    ..of CpG ODN and antigens in biodegradable nanospheres as an alternative approach for immunization using tetanus toxoid (TT) as the model antigen and ODN #1826 as the model CpG sequence...
  43. ncbi Impaired avidity maturation after tetanus toxoid booster in children with Down syndrome
    Maaike A Kusters
    Department of Pediatrics, Jeroen Bosch Hospital, s Hertogenbosch, The Netherlands
    Pediatr Infect Dis J 30:357-9. 2011
    Down syndrome children show a decreased avidity of the antibody response after tetanus toxoid booster vaccination at 9 years of age suggesting impaired memory B cell selection in the germinal center...
  44. ncbi Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating β-glucan
    Tomasz Lipinski
    Department of Chemistry, Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
    J Immunol 190:4116-28. 2013
    In a previous attempt to generate a protective vaccine against Candida albicans, a β-mannan tetanus toxoid conjugate showed poor immunogenicity in mice...
  45. ncbi Human anti-FcepsilonRIalpha autoantibodies isolated from healthy donors cross-react with tetanus toxoid
    M P Horn
    Institute of Immunology and Allergology, University of Bern, Switzerland
    Eur J Immunol 29:1139-48. 1999
    ..auto-Ab showed no evidence of histamine release but strongly cross-reacted with an external antigen, tetanus toxoid (TTd) with a higher affinity for TTd than for the FcepsilonRIalpha...
  46. ncbi Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds
    David A Talan
    Department of Medicine, Division of Emergency Medicine, Olive View University of California Los Angeles Medical Center, Sylmar 91342, USA
    Ann Emerg Med 43:305-14. 2004
    ..We determine tetanus seroprotection rates and physician compliance with tetanus prophylaxis recommendations among patients presenting with wounds...
  47. ncbi Determinants of tetanus toxoid immunization in pregnancy in rural Bihar
    Amardeep Thind
    Department of Health Services, UCLA School of Public Health, Room 31 299 CHS, Box 951772, Los Angeles, CA 90095 1772, USA
    Trop Doct 35:75-7. 2005
    In order to increase the uptake of tetanus toxoid (TT) vaccination, we need to understand the factors that underlie the decision of the pregnant woman to undergo vaccination, especially in rural areas, where 75% of India's population ..
  48. ncbi Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens
    R Dagan
    Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
    Pediatr Infect Dis J 16:1053-9. 1997
    ..We assessed in young infants the safety and immunogenicity of two tetravalent vaccines containing pneumococcal 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid (Pnc-T) or diphtheria toxoid (Pnc-D).
  49. ncbi Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials
    Wayde M Weston
    GSK Biologicals, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Vaccine 30:1721-8. 2012
    ..Pertussis can cause significant morbidity in elderly patients, who can also transmit this disease to infants and young children. There is little data available on the use of acellular pertussis vaccines in recipients ≥65 years of age...
  50. ncbi The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine
    Ghassan Dbaibo
    Center for Infectious Diseases Research, American University of Beirut, PO Box 11 0236, Riad El Solh, Beirut 1107 2020, Lebanon
    Int J Infect Dis 16:e608-15. 2012
    The immunogenicity and safety of the tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) were evaluated in subjects previously vaccinated with a tetravalent meningococcal polysaccharide ..
  51. ncbi [Regional variations of adult population vaccinal status]
    J Beytout
    Service de Maladies Infectieuses, Hotel Dieu, Clermont Ferrand, France
    Med Mal Infect 34:460-8. 2004
    ..The authors had for aim to study the regional variations of vaccination coverage in adult population...
  52. ncbi Appropriate tetanus prophylaxis practices in patients attending Emergency Departments in Italy
    Rossella Abbate
    Department of Public, Clinical and Preventive Medicine, Second University of Naples, Via Luciano Armanni, 5, 80138 Naples, Italy
    Vaccine 26:3634-9. 2008
    ..This study evaluated the physician compliance with tetanus prophylaxis and immunization practices for patients with wounds attending Emergency Departments (EDs) of four randomly selected non-academic acute care public hospitals in Italy...
  53. pmc Maternal tetanus toxoid vaccination and neonatal mortality in rural north India
    Abhishek Singh
    Global Health and Social Care Unit, School of Health Sciences and Social Work, University of Portsmouth, Portsmouth, United Kingdom
    PLoS ONE 7:e48891. 2012
    ..Preventable neonatal mortality due to tetanus infection remains common. We aimed to examine antenatal vaccination impact in a context of continuing high neonatal mortality in rural northern India...
  54. pmc Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice
    Robert W Maitta
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Infect Immun 72:196-208. 2004
    ..P13 was conjugated to tetanus toxoid (TT) or diphtheria toxoid (DT) and administered subcutaneously in Alhydrogel with or without CpG to mice ..
  55. ncbi Proteins and their derived peptides as carriers in a conjugate vaccine for Streptococcus pneumoniae: self-heat shock protein 60 and tetanus toxoid
    Hila Amir-Kroll
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    J Immunol 170:6165-71. 2003
    ..to the capsular polysaccharide (CPS) of type 4 Pn; the carriers were self-heat shock protein 60 (HSP60) and tetanus toxoid (TT)...
  56. ncbi Tetanus antigen modulates the gene expression profile of aluminum phosphate adjuvant in spleen lymphocytes in vivo
    K Regnstrom
    Department of Pharmacy, Uppsala University, Sweden
    Pharmacogenomics J 2:57-64. 2002
    ..profiles from spleen lymphocytes after in vivo immunization of mice with a clinically relevant vaccine, tetanus toxoid formulated with aluminum phosphate as adjuvant (TT(ADJ)), or the adjuvant alone (ADJ)...
  57. ncbi Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules
    Michael E Pichichero
    Microbiology and Immunology, Pediatrics and Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA
    Clin Pediatr (Phila) 45:613-20. 2006
    ..Seroprotective levels and antibody concentrations were comparable regardless of prior DTaP/DTwP vaccine history. A sixth sequential dose of Tdap after 5 doses of DTaP appears safe and immunogenic...
  58. ncbi Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres
    K S Jaganathan
    Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr Hari Singh Gour University, Sagar, Madhya Pradesh 470003 India
    Int J Pharm 294:23-32. 2005
    Stable polymeric microspheres capable of controlled release of tetanus toxoid (TT) for periods ranging from days to over months were developed...
  59. ncbi Synthesis and immunochemical studies on a Candida albicans cluster glycoconjugate vaccine
    Xiangyang Wu
    Alberta Ingenuity Centre for Carbohydrate Science, Department of Chemistry, University of Alberta, Edmonton, AB T6G 2G2, Canada
    Org Biomol Chem 5:3477-85. 2007
    ..The clustered epitopes were conjugated to tetanus toxoid and bovine serum albumin...
  60. ncbi Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen
    María Victoria Lavigne
    Instituto de Estudios de la Inmunidad Humoral, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Junin 956, 1113 Buenos Aires, Argentina
    Microbes Infect 4:815-20. 2002
    ..Th1/Th2 cell differentiation during the immune response to another antigen, we analysed the immune response to tetanus toxoid (soluble antigen) in BALB/c mice immunized with one of the three following vaccines: tetanus and diphtheria ..
  61. ncbi Glycoconjugate vaccines and immune interference: A review
    Ron Dagan
    The Pediatric Infectious Disease Unit, The Faculty of Health Sciences, Ben Gurion University of the Negev and Soroka University Medical Center, Beer Sheva, Israel
    Vaccine 28:5513-23. 2010
    ..The widely used carrier proteins are tetanus toxoid (TT), diphtheria toxoid (DT) and diphtheria toxoid variant CRM197 protein, DT conjugates being in general less ..
  62. ncbi Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with
    Pirmin Habermehl
    Children s Hospital, University of Mainz, Germany
    Hum Vaccin 6:640-51. 2010
    ..study 792014 and 100381;www.clinicaltrial.govID:NCT00129116)..
  63. ncbi Lymphocyte responses to influenza and tetanus toxoid in vitro following intensive exercise and carbohydrate ingestion on consecutive days
    Nicolette C Bishop
    School of Sport and Exercise Sciences, Loughborough University, Leicestershire, UK
    J Appl Physiol (1985) 99:1327-35. 2005
    ..This study investigated the effect of CHO ingestion during prolonged, intensive exercise on influenza- and tetanus toxoid-stimulated T-cell cytokine mRNA expression and proliferation...
  64. ncbi Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid
    R Dagan
    Pediatric Infectious Disease Unit, Soroka Medical Center and the Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
    Pediatr Infect Dis J 16:1060-4. 1997
    ..Pneumococcal nasopharyngeal colonization is important for transmission of the organisms. We assessed the ability of two tetravalent conjugate vaccines administered in early infancy to prevent carriage of vaccine-related pneumococci...
  65. ncbi Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres
    S Abolghasem Sajadi Tabassi
    School of Pharmacy, Mashhad University of Medical Sciences, P O Box 91775 1365, Mashhad, Iran
    Int J Pharm 360:12-7. 2008
    ..Cross-linked dextran microspheres (CDMs) were loaded with tetanus toxoid (TT). In vitro release studies were performed in a model, simulating the nasal cavity...
  66. ncbi Physician compliance with tetanus guidelines for admitted versus discharged patients
    Kumar Alagappan
    Department of Emergency Medicine, North Shore, Long Island Jewish Health System, New Hyde Park, NY, USA
    South Med J 99:234-8. 2006
    ..Despite a propensity to present with tetanus-prone wounds, patients admitted to the hospital were less likely to receive tetanus immunoprophylaxis in accordance with ACIP guidelines...
  67. ncbi Avidity of tetanus and Hib antibodies after childhood acute lymphoblastic leukaemia - implications for vaccination strategies
    Torben Ek
    Department of Paediatrics, Goteborg University, The Queen Silvia Children s Hospital, Goteborg, Sweden
    Acta Paediatr 95:701-6. 2006
    To investigate the possible relationship between serum levels and avidities of antibodies against tetanus toxoid (TT) and Haemophilus influenzae type b (Hib) in children that were vaccinated after treatment for childhood acute ..
  68. pmc A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action
    A J MacDonald
    iQur Ltd, Mailpoint 811, Southampton General Hospital, Southampton, UK
    Clin Exp Immunol 152:265-73. 2008
    ..Recall responses of normal healthy donor (NHD) and chronic hepatitis C virus (c-HCV)-infected patient PBMC to tetanus toxoid (TT) or HCV core (HCVco) antigen, respectively, were measured by interferon-gamma enzyme-linked immunospot ..
  69. ncbi Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid
    M Korkeila
    National Public Health Institute, Helsinki, Finland
    Vaccine 18:1218-26. 2000
    ..The children received Pnc conjugate vaccine (1, 3, or 10 micrograms of PSs conjugated to diphtheria or tetanus toxoid) or placebo at 2, 4, and 6 months. At 7 months of age salivary PS antibodies were detected rarely...
  70. ncbi Chitosan microparticles as oral delivery system for tetanus toxoid
    Vijay J Ahire
    Center of Relevance and Excellence in New Drug Delivery Systems TIFAC CORE in NDDS, Department of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, India
    Drug Dev Ind Pharm 33:1112-24. 2007
    Systemic and local immune response against Chitosan encapsulated tetanus toxoid (CS-TT) microparticles is studied, prepared by ionic cross-linking using Sodium Tripolyphosphate (STPP)...
  71. pmc Comparison of three enzyme-linked immunosorbent assays for detection of immunoglobulin g antibodies to tetanus toxoid with reference standards and the impact on clinical practice
    Karen H van Hoeven
    The Binding Site, Inc, 5889 Oberlin Dr, Ste 101, San Diego, CA 92121, USA
    Clin Vaccine Immunol 15:1751-4. 2008
    Accurate determination of the concentrations of immunoglobulin G (IgG) antibody to tetanus toxoid is important in order to evaluate the immunogenicity of tetanus toxoid vaccines, determine immune competence in individual patients, and ..
  72. ncbi Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN
    Mohsen Tafaghodi
    School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
    Eur J Pharm Biopharm 64:138-45. 2006
    To increase the systemic and mucosal immune responses against the nasally administered tetanus toxoid, liposomes as a drug delivery system and CpG-ODN as an adjuvant were evaluated...
  73. ncbi Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity
    Jamie F S Mann
    Department of Immunology, Strathclyde Institute for Biomedical Sciences, John Arbuthnott Building, University of Strathclyde, Glasgow G4 0NR, UK
    Methods 38:90-5. 2006
    ..In this comparative study, mice were immunised orally with tetanus toxoid (40 or 200 microg dose/mouse, four doses in total) entrapped in non-ionic surfactant vesicles formulated with ..
  74. ncbi Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients
    Bénédicte Puissant-Lubrano
    Laboratoire d Immunologie, CHU de Toulouse, Hopital Rangueil, France
    Exp Clin Transplant 8:19-28. 2010
    Rituximab is used after kidney transplant to prevention or treat kidney-allograft rejection. However, the impact of rituximab on the ability of patients to respond to tetanus toxoid vaccination has not yet been studied.
  75. ncbi Dextran microspheres could enhance immune responses against PLGA nanospheres encapsulated with tetanus toxoid and Quillaja saponins after nasal immunization in rabbit
    Maliheh Mohaghegh
    School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
    Pharm Dev Technol 16:36-43. 2011
    ..Co-encapsulation of QS and TT in PLGA nanospheres increased sIgA titers. In conclusion, the highest immune responses were observed by concomitant use of three adjuvants...
  76. ncbi A microassay for measurement of Fc function of human immunoglobulin preparations by using tetanus toxoid as antigen
    Anto Vrdoljak
    Institute of Immunology, Rockefellerova 2, HR 10 000 Zagreb, Croatia
    Biologicals 32:78-83. 2004
    ..We present a modification of the proposed method achieved by using more convenient and readily available tetanus toxoid as an alternative antigen target and by adapting the procedure for the use on microtitre plates, thus greatly ..
  77. ncbi Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers
    Pui Y Lee
    General Clinical Research Center, University of Florida, Gainesville, FL 32610, USA
    Vaccine 24:4035-40. 2006
    ..To determine whether short-term atorvastatin treatment affects the acute phase and humoral immune responses to tetanus toxoid (TT) in normal healthy volunteers, we conducted a randomized, double blind, placebo-controlled trial...
  78. ncbi Immunization with meningococcal polysaccharide-tetanus toxoid conjugate induces polysaccharide-reactive T cells in mice
    Subramanian Muthukkumar
    Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Vaccine 22:1290-9. 2004
    ..were generated from mice immunized with a meningococcal group C (alpha2 --> 9-sialic acid) polysaccharide-tetanus toxoid (MCPS-TT) conjugate...
  79. pmc Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls
    E Konadu
    National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 64:2709-15. 1996
    ..Szu, Infect. Immun. 60:4679-4686, 1992), conjugates composed of the detoxified LPS of S. paratyphi A bound to tetanus toxoid (TT) were prepared by several schemes...
  80. ncbi Coverage and factors associated with tetanus toxoid vaccination status among females of reproductive age in Peshawar
    Naseem Khan Afridi
    Department of Health, Provincial Health Services Academy, Peshawar
    J Coll Physicians Surg Pak 15:391-5. 2005
    To estimate the coverage and determine the factors associated with tetanus toxoid vaccination status among females of reproductive age.
  81. pmc Long-term maternal effect on offspring immune response in song sparrows Melospiza melodia
    Jane M Reid
    School of Biological Sciences, Zoology Building, University of Aberdeen, Tillydrone Avenue, Aberdeen AB24 2TZ, UK
    Biol Lett 2:573-6. 2006
    ..These data demonstrate substantial long-term effects of maternal immune experience on the humoral immune response of fully grown offspring in free-living birds...
  82. pmc Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults
    Jo Southern
    Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Ave, Colindale, London, United Kingdom
    Clin Diagn Lab Immunol 11:1100-4. 2004
    ..The study shows that MCC-TT is safe and immunogenic in naive and previously MACP-vaccinated adults, though the magnitude and persistence of postvaccination SBA responses in the latter group were lower...
  83. ncbi Network connectivity is shown to change in C57BL/6 mice during a continuing immune response subsequent to tetanus toxoid hyperimmunization
    Irena P Zivkovic
    Department of Research and Development, Institute of Virology, Vaccines and Sera Torlak, Vojvode Stepe 458, Belgrade, Serbia
    Biol Res 43:393-402. 2010
    We have already demonstrated (Stojanovic et al., 2009) a connection between tetanus toxoid (TTd) hyperimmunization and the induction of anti-phospholipid syndrome (APS) in BALB/c mice...
  84. ncbi [Factors associated with tetanus vaccination coverage in adults in France and with knowledge of vaccination status]
    J P Guthmann
    Unité des maladies à prévention vaccinale, Departement des Maladies Infectieuses, Institut de Veille Sanitaire, 12, rue du Val d Osne, 94415 Saint Maurice Cedex, France
    Med Mal Infect 40:560-7. 2010
    ..The latest national figures showed that only 62% of adults were up-to-date for this vaccination. We tried to determine the factors associated with vaccination coverage and with knowledge of vaccination status...
  85. ncbi Tetanus toxoid-loaded transfersomes for topical immunization
    Prem N Gupta
    Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr Harisingh Gour University, Sagar M P 470003, India
    J Pharm Pharmacol 57:295-301. 2005
    ..deformable lipid vesicles called transfersomes were used in this study for the non-invasive delivery of tetanus toxoid (TT)...
  86. ncbi Adequate immune response to tetanus toxoid and failure of vitamin A and E supplementation to enhance antibody response in healthy children
    N Kutukculer
    Ege University, Faculty of Medicine, Department of Paediatrics, Bornova, Izmir, Turkey
    Vaccine 18:2979-84. 2000
    The effects of vitamin A and vitamin E supplementation on the IgG response to tetanus toxoid after primary immunization were evaluated in a prospective, randomized controlled clinical trial involving 89 healthy infants with normal serum ..
  87. ncbi Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age
    Robert Booy
    National Centre for Immunisation Research and Surveillance, The Children s Hospital at Westmead, Sydney, Australia
    Pediatr Infect Dis J 30:340-2. 2011
    ..15 μg/mL. After 12 months, rSBA titer ≥ 8 persisted in 86.7% and 76.4%, and anti-PRP concentration ≥ 0.15 μg/mL persisted in 98.8% and 100% of children, respectively...
  88. ncbi Frequent failure of adolescent booster responses to tetanus toxoid despite infant immunization: waning of infancy-induced immune memory?
    Klara M Posfay-Barbe
    Department of Pediatrics, University Hospitals of Geneva, Switzerland
    Vaccine 28:4356-61. 2010
    To define the capacity of a tetanus toxoid booster to reactivate infant-triggered immunity, anti-tetanus antibodies were assessed before and after boosting 162 adolescents and 219 children from Mfou (Cameroon)...
  89. ncbi The evaluation of immune responses to hepatitis B vaccination in diabetic and non-diabetic haemodialysis patients and the use of tetanus toxoid
    Sabahattin Ocak
    Department of Infectious Diseases and Clinical Microbiology, Medical Faculty, Mustafa Kemal University, Hatay, Turkey
    Nephrology (Carlton) 13:487-91. 2008
    ..from diabetes mellitus could be considered at risk for the development of the protective antibodies to hepatitis B (HB) vaccination and, to evaluate the effectiveness of tetanus toxoid (TT) administrated 2 days before HB vaccination.
  90. ncbi A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants
    David Pace
    Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Department of Paediatrics, University of Oxford, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK
    Pediatr Infect Dis J 26:1057-9. 2007
    ..and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule...
  91. ncbi Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses
    Rob Tierney
    Division of Bacteriology, National Institute for Biological Standards and Control, Potters Bar, United Kingdom
    J Infect Dis 188:753-8. 2003
    ..compared with that of a cytosine phosphodiester-guanine (CpG) motif, after transcutaneous immunization with tetanus toxoid (TT)...
  92. ncbi An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children
    Markus Knuf
    Pediatrics Infectious Diseases, University Medicine, Mainz, Germany
    Vaccine 29:4264-73. 2011
    ..ACWY-TT and DTaP-HBV-IPV/Hib co-administration during the second year would facilitate introduction of ACWY-TT into routine toddler vaccination schedules...
  93. ncbi ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid
    M A Westerink
    Department of Medicine, Medical College of Ohio, 3055 Arlington Avenue, Toledo, OH 43614, USA
    Vaccine 20:711-23. 2001
    ..In this study we have examined the effect of mucosal administration of tetanus toxoid (TT) in the presence of a non-ionic block copolymer, Pluronic F127 (F127), with chitosan or ..
  94. ncbi A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A
    Nousheen Zaidi
    Medical and Natural Sciences Research Centre, University of Tubingen, Ob dem Himmelreich 7, 72074 Tubingen, Germany
    Biochem Biophys Res Commun 364:243-9. 2007
    ..Additionally, we found that PepA-P efficiently inhibited the tetanus toxoid C-fragment processing in peripheral blood mononuclear cells (PBMC), primary DC and in primary B cells...
  95. ncbi Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine
    D P Greenberg
    UCLA Center for Vaccine Research, Harbor UCLA Medical Center, UCLA School of Medicine, Torrance, CA, USA
    Pediatr Infect Dis J 19:1135-40. 2000
    ..vaccine that contains diphtheria and tetanus toxoids and acellular pertussis antigens (DTaP), recombinant hepatitis B surface antigen (HepB) and Haemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus toxoid (PRP-T).
  96. ncbi Use of tetanus toxoid as a differentiating infected from vaccinated animals (DIVA) strategy for sero-surveillance of avian influenza virus vaccination in poultry
    Cassandra M James
    School of Veterinary and Biomedical Sciences, Division of Health Sciences, Murdoch University, South Street, Perth, 6150 Western Australia, Australia
    Vaccine 25:5892-901. 2007
    ..We propose a novel DIVA approach for chickens using tetanus toxoid (TT) as an exogenous marker independent of serotype and relatedness of circulating and vaccine strains...
  97. ncbi Antihepatitis B response to hepatitis B vaccine administered simultaneously with tetanus toxoid in nonresponder individuals
    Emine Sonmez
    Department of Infectious Diseases and Clinical Microbiology, Medical Faculty of Kadir Has University, Vefabey Sokak No 5, 80 810 Gayrettepe, Istanbul, Turkey
    Vaccine 21:243-6. 2002
    ..effect of simultaneous administration of preS2 and S containing recombinant hepatitis B vaccine (S2SRHB) with tetanus toxoid (TT) to the individuals who did not respond after three doses of hepatitis B vaccine previously...
  98. ncbi A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months
    Javier Diez-Domingo
    CSISP, Centro Superior de Investigacion en Salud Publica Center for Public Health Research, Valencia, Spain
    Pediatr Infect Dis J 29:148-52. 2010
    ..A booster meningococcal C (MenC) vaccine dose is recommended after the first year of life. The objective of this study was to assess its immunogenicity and factors that modify the immunoresponse...
  99. pmc Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects
    Lee Tay
    Clinical Discovery, Bristol Myers Squibb, PO Box 4000, Princeton, NJ 08543 4000, USA
    Arthritis Res Ther 9:R38. 2007
    ..study, the effect of a single 750 mg infusion of abatacept on the antibody response to the intramuscular tetanus toxoid vaccine (primarily a memory response to a T-cell-dependent peptide antigen) and the intramuscular 23-valent ..
  100. ncbi Risk factors for neonatal tetanus--Busoga region, Uganda, 2002-2003
    Sheba N Gitta
    Makerere University Institute of Public Health, Kampala, Uganda
    MMWR Morb Mortal Wkly Rep 55:25-30. 2006
    ..The Busoga region has the highest recorded level of NNT incidence in Uganda. To understand the reasons for this high incidence, a study was conducted to identify NNT risk factors...
  101. ncbi Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines
    Robin E Huebner
    Respiratory and Meningeal Pathogens Research Unit of the Medical Research Council, National Health Laboratory Service and the University of the Witwatersrand, Johannesburg, South Africa
    Vaccine 23:802-6. 2004
    ..625, 1.25, 2.5, 5.0 and 10 microg) of either a diphtheria CRM197 or tetanus toxoid-conjugated Hib vaccine...

Research Grants62

  1. Transgenesis and Xenotransplantation
    Jorge A Piedrahita; Fiscal Year: 2013
    ..leukocyte cultures, and examining novel T- cell specificities by immunizing with parvovirus, pseudorabies, and tetanus toxoid. Aim 3. To develop a transgenic pig that will facilitate engraftment and proliferation of human hepatocytes...
  2. Inhibiting Mucosal HIV-1 Transmission by Host Cell RNA Interference
    Alexandra L Howell; Fiscal Year: 2013
    ..leukocytes in mucosal tissues of NOD/SCID/BLT mice enhances immune responses to HIV-1 and to a model antigen, tetanus toxoid (specific aim 2)...
  3. Developing Immunotherapeutics for Methamphetamine Abuse
    THOMAS RICHARD KOSTEN; Fiscal Year: 2010
    ..Four carriers will be compared: Tetanus toxoid, neisseria meningitidis outer membrane protein (OMPC), cholera toxin B and a new lipopeptide based, self-..
  4. Preclinical studies of a heroin/morphine vaccine for opiate addiction
    Paul R Pentel; Fiscal Year: 2013
    ..We (Anton lab) recently developed a highly immunogenic second-generation vaccine (morphine conjugated to tetanus toxoid;M-TT) directed against heroin and each of its active metabolites (6-MAM, morphine, morphine-6- gluc)...
  5. Tomotherapy and Hematopoietic Stem Cells For Tolerance to Kidney Transplants
    Samuel Strober; Fiscal Year: 2013
    ..as well as recall T cell responses to herpes zoster, herpes simplex, cytomegalovirus antigens, and tetanus toxoid. In addition, we will determine T cell recovery and thymic function after transplantation by measuring the ..
  6. Impact of Sunflower Oil Massage on Neonatal Mortality in Nepal
    Luke C Mullany; Fiscal Year: 2013
    ..area will be recruited mid-pregnancy, and provided with a set of common basic antenatal interventions (tetanus toxoid, clean delivery kit, iron-folate supplements, and basic educational messages)...
  7. Induction of Tolerance to Factor VIII in Hemophilia
    DAVID WILLIAM SCOTT; Fiscal Year: 2012
    ..modulate the responsiveness of non-human primate T cells using B-cell gene therapy as follows: T cells from tetanus toxoid- and fVIII-vaccinated cynomolgus monkeys will be cultured with B cells transduced with a TT-Ig or fVIII-Ig ..
  8. A Study of Heterologous Immunity Induced by Neonatal BCG Vaccination
    Daniel H Libraty; Fiscal Year: 2012
    ..case-control study will be conducted comparing T-cell and antibody responses to the first (priming) doses of tetanus toxoid, live attenuated oral polio virus, and hepatitis B vaccination in infants with prior neonatal BCG vaccination ..
  9. Synthetic glycopeptide vaccines that enhance resistance to candidiasis
    Hong Xin; Fiscal Year: 2013
    ..Most recently, we demonstrated that addition of tetanus toxoid to the synthetic glycopeptide conjugate vaccine induced antibody-dependent protective immunity without the ..
  10. Defining T cell epitopes in Dengue virus infection
    Ramila Philip; Fiscal Year: 2013
    ..system that incorporates Toll Like Receptor (TLR) agonist, a promiscuous synthetic T helper peptide from tetanus toxoid and the bacterial mimetic GlcNAc as adjuvants and assess in vitro and in vivo for CTL activation and toxicity ..
  11. IMMUNE MONITORING OF ANTIGEN SPECIFIC THERAPY
    David Hafler; Fiscal Year: 2000
    ..Changes in precursor frequencies will be compared to tetanus toxoid (TT)...
  12. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2003
    ..To develop this approach, we have available a unique model system including Th cells against tetanus toxoid and a cDNA fragment encoding the tetanus toxoid-associated Th epitope...
  13. MOLECULAR CLONING OF HLA CLASS II TUMOR ANTIGENS
    Dorothee Herlyn; Fiscal Year: 2000
    ..To develop this approach, we have available a unique model system including Th cells against tetanus toxoid and a cDNA fragment encoding the tetanus toxoid-associated Th epitope...
  14. AUTOCRINE GROWTH FACTORS--EFFECT OF IMMUNONEUTRALIZATION
    Peter Ravdin; Fiscal Year: 1993
    ..to inhibit the growth of autocrine peptide dependent tumors? Active immunization with beta-HCG conjugated to tetanus toxoid has been used successfully in human contraception trials...
  15. IMMUNOLOGY OF BACTERIAL PNEUMONIA IN HTLV-II INFECTION
    GARY JARVIS; Fiscal Year: 2002
    ..The same individuals will also be vaccinated with tetanus toxoid protein antigen as a control for antibody response to a separate class of antigen, and their antibody ..
  16. SYNTHETIC PEPTIDE VACCINES FOR DENTAL CARIES
    Martin Taubman; Fiscal Year: 2005
    ..of GTF previously shown to induce protective responses, well be incorporated into conjugate vaccines with tetanus toxoid (TT)...
  17. Multi-componet Vaccine for Staphylcoccus epidermidis
    Tomas Maira Litran; Fiscal Year: 2009
    ..20-mer synthetic PGA peptides of either the D or L configuration and dPNAG conjugated to the carrier protein tetanus toxoid. The in vitro opsonophagocytic assay will be used as the first screen for potentially protective antibodies...
  18. A novel model for the study of primary immunodeficiency: the equine CVID
    MARIA FLAMINIO; Fiscal Year: 2009
    ..We also propose to develop a horse-mouse chimera (SCID-Eq) to complement studies in the immunodeficient horse. Our objective is to investigate new strategies that explore the patients'own immune defense to improve clinical outcome. ..
  19. MULTIPLE-SCLEROSIS: A CD40 LIGAND ANTAGONIST
    Lloyd Kasper; Fiscal Year: 2005
    ..status of the MBP-MHCII-Ig binding T cells will be determined in vitro as well as T and B cell recall to tetanus toxoid. An additional secondary outcome will be to assess change in the cognitive impairment index in response to ..
  20. MULTIPLE-SCLEROSIS: A CD40 LIGAND ANTAGONIST
    Lloyd Kasper; Fiscal Year: 2003
    ..status of the MBP-MHCII-Ig binding T cells will be determined in vitro as well as T and B cell recall to tetanus toxoid. An additional secondary outcome will be to assess change in the cognitive impairment index in response to ..
  21. CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITY
    Daniel Smith; Fiscal Year: 2007
    ..immune response after local induction with alum-associated and[unreadable] microencapsulated tetanus toxoid will be measured...
  22. EFFECTS OF LEAD ON THE IMMUNE SYSTEM OF CHILDREN
    Paula Lutz; Fiscal Year: 1990
    ..Planned assays to assess function of B-lymphocytes are serum Ig concentrations; specific antibody titer vs. tetanus toxoid, measles, or polio; and B cell count...
  23. CANCER PATIENTS IMMUNE RESPONSES STUDIED IN SCID MICE
    Dorothee Herlyn; Fiscal Year: 1992
    ..we will first optimize reconstitution of the mice with human peripheral blood mononuclear cells (PBMC) using tetanus toxoid as a model antigen...
  24. A novel vaccine/adjuvant for Streptococcus pneumoniae
    M A Westerink; Fiscal Year: 2003
    ..both systemic and mucosal adjuvant/delivery vehicles by studying the immune response in mice to the antigens tetanus toxoid, diphtheria toxoid and anthrax recombinant protective antigen with F 127 in combination with selected ..
  25. GENETIC CONTROL OF ANTIBODY RESPONSES TO POLYSACCHARIDES
    Dan Granoff; Fiscal Year: 1993
    ..In Aim 2, we will immunize healthy adults with meningococcal A and C PS and tetanus toxoid vaccines and compare their respective IgG2 antibody responses in relation to G2m(23) allotype status to ..
  26. Effectiveness of Hospital-Based Program for Vaccination of Birth Mothers and Hous
    Sylvia Yeh; Fiscal Year: 2009
    ..that persons who have close contact with young infants receive influenza vaccine as well as combined tetanus toxoid, diphtheria toxoid and reduced dose acellular pertussis vaccine (Tdap)...
  27. CONJUGATE VACCINES DESIGNED TO PREVENT TYPHOID FEVER
    HA KHIEM; Fiscal Year: 2000
    ..Of Vi -rEPA (Vi- recombinant exoprotein A of Pseudomonas aeroginosa) and S para A-TT (Salmonella paratyphi A -tetanus toxoid) investigational vaccines developed by the NICHD, NIH, Vi and S...
  28. LEUKOCYTES AND PATIENTS WITH VENOUS STASIS ULCERS
    Peter Pappas; Fiscal Year: 1999
    ..by the degree of proliferation (measured a thymidine uptake into DNA) in response to antigenic challenges with tetanus toxoid and candida mitogenic challenges with staphylococcal enterotoxins (SEs) A, B, C1 , D, E and phytohemagglutinin ..
  29. VITAMIN A THERAPY IN PRETERM INFANTS: VACCINE RESPONSE
    Mark Ballow; Fiscal Year: 2002
    ..Plasma immunoglobulins and antibodies to HbsAg and tetanus toxoid will be quantified by ELISA after the second and third doses of hepatitis B vaccine...
  30. ADJUVANTICITY OF STEARYL-TYROSINE--SUBUNIT & HIV SYSTEM
    Constantin Bona; Fiscal Year: 1991
    ..a stronger adjuvant activity than Alum ith respect to the enhancement of antibody response elicited by tetanus toxoid, poliovirus vaccine, hepatitis B surface antigen and two synthetic peptides derived from the HIV gpl2O protein...
  31. MUCOSAL IMMUNITY AND ORAL TOLERANCE--INNATE IMMUNITY
    Carol Tacket; Fiscal Year: 2001
    ..We will use novel live recombinant enteric bacterial vectors (attenuated S. typhi expressing recombinant tetanus toxoid fragment C) and transgenic plant foods expressing vaccine antigens (transgenic potato expressing hepatitis B ..
  32. Endotoxin Exposure Alters-Anti-Tetanus IgE in Infants
    Dennis Ownby; Fiscal Year: 2009
    ..environmental endotoxin exposure will be associated with reduced anti-tetanus IgE (aT-IgE) responses following tetanus toxoid immunizations...
  33. ROLE OF ANTIGEN TRANSPORT BY DENDRITIC CELLS IN AGING
    ANDRAS SZAKAL; Fiscal Year: 1993
    ..ability of the aged to produce a secondary antibody response to booster immunizations with antigens such as tetanus toxoid. Morphological and phenotypic evidence with anti-FDC monoclonal antibodies suggest that ATCs are pre-FDCs...
  34. CELLULAR MECHANISMS OF GERMINAL CENTER REACTION IN AGING
    ANDRAS SZAKAL; Fiscal Year: 2001
    ..Clinically, this correlates with the decreased secondary antibody responses to tetanus toxoid and flu vaccines...
  35. Newborn Antiseptic Washing and Neonatal Mortality-Nepal
    James Tielsch; Fiscal Year: 2005
    ..All mothers in the study will receive tetanus toxoid during pregnancy and a clean birthing kit...
  36. Endotoxin Exposure Alters Anti-Tetenus IgE in Infants
    Dennis Ownby; Fiscal Year: 2004
    ..exposure will be associated with reduced anti-tetanus IgE responses following routine immunizations with tetanus toxoid in infancy...
  37. IMMUNE CELL COOPERATION IN HUMAN HAPLOIDENTICAL CHIMERA
    JOSEPH ROBERTS; Fiscal Year: 1990
    ..Lymphocyte responses will be quantified by 3H thymidine incorporation studies of tetanus toxoid-specific T cell lines derived from the recipients and donors when presented antigen by various EBV-transformed ..
  38. IGA RECEPTORS ON HUMAN PHAGOCYTES
    LILIAN SHEN; Fiscal Year: 2000
    ..These experiments will utilize chimeric human IgA of known binding specificity to produce defined IgA-Tetanus toxoid (TT) complexes that will be used to study FcaR-directed internalization, processing and presentation of ..
  39. QUANTITATIVE ASSESSMENT OF HIV SPECIFIC IMMUNE RESPONSES
    CAROLINE WHITACRE; Fiscal Year: 1990
    ..following HIV infection is the ability of T lymphocytes to proliferate in response to soluble antigens such as tetanus toxoid. We have obtained preliminary data showing that detectable frequencies of tetanus-reactive lymphocytes are ..
  40. DENDRITIC CELL MOBILIZATION AND ACTIVE IMMUNOTHERAPY
    Herbert Lyerly; Fiscal Year: 2005
    ..We found that a single immunization with recall antigen (tetanus toxoid = TT) loaded DC lead to a significant circulating T helper response, whereas multiple immunizations with ..
  41. PEPTIDE BASED VACCINES FOR STAGE IV MELANOMA
    Craig Slingluff; Fiscal Year: 2000
    ..Both vaccines will also comprise a tetanus toxoid peptide which stimulates helper T-cell responses in the majority of humans...
  42. Mice with Human Dendritic Cells to Test Vaccine Potency
    A Palucka; Fiscal Year: 2004
    ..including their capacity to induce vaccine specific cellular (CD4 mediated) and humoral immune responses using Tetanus Toxoid as a model vaccine...
  43. Developing Broadly Neutralizing MAbs for an HIV Vaccine
    Yu Geng; Fiscal Year: 2007
    ..2) Prepare gp120-tetanus toxoid conjugates, immunize mice and screen immune sera for cross-reactive antibodies to gp120s from different ..
  44. ONTOGENY & B-CELL DEVELOPMENT IN VLBW PREMATURE INFANTS
    Mark Ballow; Fiscal Year: 1991
    ..and VK gene families in EBV-transformed B-cell lines secreting antibodies to pneumococcal polysaccharide and tetanus toxoid antigens...
  45. IMMUNE RECONSTITUTION AFTER TRANSPLANTION
    Michael Shaw; Fiscal Year: 2003
    ..Breast cancer patients undergoing HDC and stem cell transplantation will be vaccinated against tetanus toxoid and against the tumor-associated Muc-1 peptide...
  46. An in-situ gelling nasal vaccine delivery platform
    YAWEI NI; Fiscal Year: 2005
    ..vaccine delivery vehicle will be demonstrated using different types of antigens including proteins (DT-CRM and tetanus toxoid), polysaccharide-protein conjugate (Haemophilus influenzae b polysaccharide-protein conjugate), and viral ..
  47. INDUCTION OF IMMUNE TOLERANCE TO DNA: THERAPY FOR SLE
    DAVID BING; Fiscal Year: 1990
    ..In addition, DNA digest linked to either KLH or tetanus toxoid will be used to develop an antigen specific model using normal lymphoid cells from various sources or SLE ..
  48. ANTIBODY SYNTHESIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
    KENNETH NIES; Fiscal Year: 1980
    ..By studying both antigen-specific (anti-tetanus toxoid) and total immunoglobulin production both in vitro and in vivo, a few observations have been made...
  49. ANTIGEN RECOGNITION BY GAMMA-DELTA T CELL RECEPTOR
    Hamid Band; Fiscal Year: 1993
    ..Here we wish to generate tetanus toxoid (TT)- specific human gamma-delta T cell clones by in vitro stimulation of gamma-delta T cell-enriched ..
  50. Physical Activity, Aging and Immune Function
    Jeffrey Woods; Fiscal Year: 2005
    ..including the delayed-type hypersensitivity response to a battery of antigens and the antibody response to tetanus toxoid and influenza virus vaccination will be assessed before, during and after the intervention...
  51. REGULATION OF ADRENAL FUNCTION IN FIBROMYALGIA
    GAIL ADLER; Fiscal Year: 2001
    ..to three stimuli: hypoglycemia, metapyrone-induced glucocorticoid administration, and an immune stimulus with tetanus toxoid vaccine. In Specific Aim 2, sypathoadrenal responses to hypoglycemia, the cold pressor test, metapyrone vs...
  52. Anxiety and Delayed Type Hypersensitivity Responses
    Mark Larson; Fiscal Year: 2002
    ..acute stress), spaced two weeks apart, which would be counterbalanced. Injection of tetanus toxoid at the end of each session would serve to initiate the DTH response, and subjects would be required to return ..
  53. AGING AND ANTIBODY RESPONSE IN RESPIRATORY SECRETION
    Masakazu Matsumoto; Fiscal Year: 1980
    ..e. young adult (16 weeks old), middle-aged (65 week old) and aged (100 weeks old) will be immunized with tetanus toxoid, influenza virus or purified pneumococcal polysaccharide via respiratory route...
  54. SAFETY AND IMMUNOGENICITY OF AN INVESTIGATIONAL VACCINE
    JAMES PARKE; Fiscal Year: 1991
    ..and efficacy of a new Hemophilus influenzae type b (Hib) vaccine (Hib capsular polysaccharide conjugated with tetanus toxoid) developed by NICHD scientists...
  55. MATERNO-FETAL HIV TRANSMISSION - MODEL FOR VACCINES
    ARYE RUBENSTEIN; Fiscal Year: 1993
    ..For that purpose MN-PND peptides will be conjugated to tetanus toxoid or to PPD for immunization of HIV seropositive women who have a high robability of becoming pregnant within ..
  56. Development of a Global GBS Vaccine
    LAWRENCE PAOLETTI; Fiscal Year: 2007
    ..This work will lead to a vaccine effective in preventing GBS diseases worldwide. ..
  57. Bacterial Vaccine Antigen Discovery
    LAWRENCE PAOLETTI; Fiscal Year: 2006
    ..Aim 2). Findings from these studies utilizing this unique approach to vaccine antigen discovery could be directly applied to other bacterial pathogens. ..
  58. Motor Neuron Protection through Glutamate Degradation
    Paul Fishman; Fiscal Year: 2002
    ....
  59. Unique Neisseria Meningitidis B Capsular Epitopes
    GREGORY MOE; Fiscal Year: 2009
    ..Thus, this proposal offers a novel approach to develop a protective PS-based vaccine that avoids safety concerns of eliciting autoantibodies and for understanding structural differences between group B capsular and host PSA antigens. ..
  60. CD4 Immune Reconstitution in SIV Infection
    Francois Villinger; Fiscal Year: 2007
    ..Results of these studies will form the basis for future immune reconstitution strategies in human HIV infected patients. ..
  61. Parathyroid and Thymus Transplants in DiGeorge Syndrome
    MARY MARKERT; Fiscal Year: 2005
    ..Indirect allorecognition as a mechanism of graft rejection will be assessed by ELISpot. The third aim will assess safety and tolerability. ..